Ilex/Millennium Campath
Executive Summary
Design of post-approval commitment trial under discussion with FDA following receipt of "complete review" letter for the chronic lymphocytic leukemia treatment, Millennium reports. Campath is on track for approval in first quarter, the company says. FDA's Oncologic Drugs Advisory Committee voted 14-1 in favor of accelerated approval of alemtuzumab but was undecided on the design of the post-approval comparative study (1"The Pink Sheet" Dec. 18, 2000, p. 17)